Neoadjuvant Chemotherapy Therapy News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Chemotherapy Induces Molecular Changes in High-Grade Serous Ovarian Carcinoma
Molecular expression analysis found that high-grade serous ovarian carcinomas exhibit significant alterations to cell cycle genes, DNA damage genes, and other pathways following treatment with neoadjuvant chemotherapy. (Source: CancerNetwork)
Source: CancerNetwork - March 14, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Gynecologic Cancers News Ovarian Cancer Conferences/SGO 2017 Source Type: news

Novel calculator more easily identifies patients who will benefit from neoadjuvant chemoradiation
A calculator to guide treatment choice in esophageal cancer has been developed by a team of researchers. The tool helps identify which patients may benefit from treatment before surgery. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 2, 2017 Category: Science Source Type: news

Optimizing Outcomes for Patients With Curable Bladder Cancer
This video highlights emerging data on genomic markers of response to neoadjuvant chemotherapy for patients with bladder cancer. (Source: CancerNetwork)
Source: CancerNetwork - February 20, 2017 Category: Cancer & Oncology Authors: Elizabeth R. Plimack, MD, MS Tags: ASCO Genitourinary Cancers Symposium Videos Genitourinary Cancers Source Type: news

Genomic Subtyping Could Guide Treatment Decisions for Bladder Cancer
Genomic subtyping of muscle-invasive bladder cancer could inform decisions on when best to use neoadjuvant cisplatin-based chemotherapy, according to a retrospective, non-randomized study. (Source: CancerNetwork)
Source: CancerNetwork - February 19, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: ASCO Genitourinary Cancers Symposium Bladder Cancer News Source Type: news

Esophageal cancer: Loss of muscle mass represents a significant risk to survival
Esophageal cancer patients who suffer loss of muscle mass (sarcopenia) during neoadjuvant therapy (chemotherapy prior to surgery) survive, on average, 32 months less than patients with no sarcopenia, new research concludes. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 14, 2017 Category: Science Source Type: news

Bioselective Treatment Improves Survival in Advanced Laryngeal Cancer Bioselective Treatment Improves Survival in Advanced Laryngeal Cancer
Tumor response to a single cycle of neoadjuvant chemotherapy helps pinpoint appropriate treatment for patients with advanced laryngeal cancer, researchers say.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 13, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Residual Cancer Burden Prognostic Across Breast Cancer Phenotypes
Residual cancer burden was found to be prognostic for long-term survival following neoadjuvant chemotherapy for three phenotypic subsets of breast cancer in a new single-institution study. (Source: CancerNetwork)
Source: CancerNetwork - February 6, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer News Source Type: news

More Data Needed on Watch-and-Wait Strategy for Rectal Cancer
Using a watch-and-wait strategy among a group of highly selected patients with rectal cancer who have undergone neoadjuvant chemoradiation did not appear to compromise outcomes. (Source: CancerNetwork)
Source: CancerNetwork - January 18, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Conferences/ASCO 2017 Gastrointestinal Cancers Symposium Conference Report Source Type: news

FDA grants Roche ’s cancer immunotherapy TECENTRIQ(atezolizumab) Priority Review in additional type of advanced bladder cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for TECENTRIQ® (atezolizumab) for the treatment of people with locally advanced or metastatic urothelial carcinoma (mUC) who are ineligible for cisplatin chemotherapy, and are either previously untreated (first-line) or have disease progression at least 12 months after receiving chemotherapy before surgery (neoadjuvant) or after surgery (adjuvant). (Source: Roche Investor Update)
Source: Roche Investor Update - January 9, 2017 Category: Pharmaceuticals Source Type: news

FDA grants Roche ’s cancer immunotherapy TECENTRIQ(atezolizumab) Priority Review in additional type of advanced bladder cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for TECENTRIQ® (atezolizumab) for the treatment of people with locally advanced or metastatic urothelial carcinoma (mUC) who are ineligible for cisplatin chemotherapy, and are either previously untreated (first-line) or have disease progression at least 12 months after receiving chemotherapy before surgery (neoadjuvant) or after surgery (adjuvant). (Source: Roche Media News)
Source: Roche Media News - January 9, 2017 Category: Pharmaceuticals Source Type: news

AI Neither Adds nor Detracts From Chemo in This Setting AI Neither Adds nor Detracts From Chemo in This Setting
The addition of endocrine deprivation therapy to neoadjuvant chemotherapy doesn ' t increase pathologic complete response rates in hormone receptor-positive, HER2-positive breast cancer, but it doesn ' t diminish the effectiveness of chemotherapy either, as has long been believed.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 14, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Scalp-Cooling System Reduced Hair Loss From Breast Cancer Chemotherapy
With the help of a scalp-cooling device, 50% of women with breast cancer undergoing neoadjuvant or adjuvant chemotherapy were able to prevent hair loss, according to the results of the SCALP trial. (Source: CancerNetwork)
Source: CancerNetwork - December 10, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: News Conferences/SABCS 2016 Source Type: news

Image-guided biopsy identifies patients who achieve pathologic complete response after neoadjuvant therapy
In a pilot study, image-guided biopsies identified select breast cancer patients who achieved pathologic complete response (pCR) after chemotherapy and/or targeted therapy, neoadjuvant systemic therapy (NST). (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 9, 2016 Category: Science Source Type: news

Image-guided biopsy identifies patients who achieve pathologic complete response after neoadjuvant therapy
(University of Texas M. D. Anderson Cancer Center) In a pilot study conducted at The University of Texas MD Anderson Cancer Center, image-guided biopsies identified select breast cancer patients who achieved pathologic complete response (pCR) after chemotherapy and/or targeted therapy, neoadjuvant systemic therapy (NST). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 9, 2016 Category: Cancer & Oncology Source Type: news

No Benefit in Adding AI to Neoadjuvant Treatment for HR+/HER2+ Breast Cancer
The addition of estrogen deprivation to neoadjuvant chemotherapy did not significantly affect pathologic complete response in women with HR-positive, HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - December 8, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: HER2-Positive Breast Cancer News Conferences/SABCS 2016 Source Type: news